BeyondSpring Inc. (BYSI) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, primarily its lead asset Plinabulin. The company operates as a non-accelerated filer and smaller reporting company. A significant strategic shift occurred in late 2024 with the decision to divest its Targeted Protein Degradation (TPD) platform, SEED Therapeutics Inc., which is now reported as discontinued operations.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 | $0 | $0 |
| Revenue (Discontinued Ops) | $0.5M | $0.5M | $1.5M | $1.5M |
| Net Loss (Total) | $(4.9M) | $(4.6M) | $(8.4M) | $(12.0M) |
| Net Loss (Continuing Ops) | $(1.7M) | $(2.2M) | $(6.2M) | $(6.9M) |
| Net Loss (Discontinued Ops) | $(3.2M) | $(2.4M) | $(2.2M) | $(5.0M) |
| EPS (Basic & Diluted) | $(0.04) | $(0.05) | $0.03 | $(0.24) |
| Cash & Equivalents (Continuing) | $12.5M | $19.3M | $12.5M | $19.3M |
| Accumulated Deficit | $(406.3M) | $(405.7M) | $(406.3M) | $(405.7M) |
Note: YTD 2025 Net Loss includes a one-time gain of $7.0M from the sale of SEED subsidiary interests, resulting in a net income attributable to BeyondSpring Inc. of $1.1M for the nine-month period, despite operating losses.
Material Changes vs. Prior Period
- Discontinued Operations: The divestiture of SEED Therapeutics (TPD platform) is the primary driver of financial changes. In Q3 2025, the company recorded a $7.0M gain on the sale of subsidiary interests (First Closing of the divestiture), significantly offsetting operating losses for the nine-month period.
- Operating Expenses (Continuing):
- R&D Expenses: Increased 67% QoQ (3-month) and 34% YTD to $1.0M and $2.9M respectively, driven by higher drug manufacturing costs, regulatory professional services, and Plinabulin combination therapy research.
- G&A Expenses: Decreased 57% QoQ (3-month) and 30% YTD to $0.8M and $3.4M respectively, due to reduced administrative headcount and lower professional service costs.
- Liquidity: Cash and cash equivalents from continuing operations increased from $2.9M at year-end 2024 to $12.5M at September 30, 2025, bolstered by proceeds from the SEED divestiture and investment maturities.
Guidance, Outlook, and Risks
- Plinabulin Pipeline: The company continues to advance Plinabulin, particularly in Non-Small Cell Lung Cancer (NSCLC). The DUBLIN-3 Phase 3 study showed statistically significant overall survival benefits. The company plans to file a New Drug Application (NDA) with China's NMPA as soon as possible.
- SEED Divestiture: The company expects to receive an additional $28.1M in tranches from the remaining closings of the SEED share sales (Second Closing by Dec 2025, Third Closing by Dec 2026).
- Liquidity Outlook: Management anticipates current resources will fund operations for the next 12 months. However, substantial additional funding will be required for future clinical development and commercialization.
- Risks:
- Dependence on the success of clinical trials and regulatory approvals for Plinabulin.
- Need for additional financing; inability to raise capital could force delays or termination of programs.
- Regulatory risks regarding the NDA filing and potential FDA concerns from previous submissions.
- Market volatility and macroeconomic factors affecting capital availability.
Investor Verification Checklist
- SEED Divestiture Timeline: Verify the status and expected closing dates of the Second and Third closings of the SEED share sales to confirm the $28.1M expected proceeds.
- Plinabulin NDA Status: Confirm the timeline for the NDA submission to the NMPA in China and any updates on the FDA Complete Response Letter from 2021.
- Cash Burn Rate: Analyze the run-rate of cash consumption from continuing operations ($14.3M used in 9 months) against the $12.5M cash balance to assess the true runway without the SEED proceeds.
- Deferred Revenue: Review the $28.1M deferred revenue balance (primarily from Hengrui collaboration) and the conditions required for recognition (product approval).
- Debt Obligations: Confirm the status of the $4.3M short-term loans associated with discontinued operations and ensure no cross-default risks exist for continuing operations.